Clinical trial / 2008
Short-term metformin administration slightly reduced peak aerobic capacity and exercise duration in healthy individuals.
Seventeen healthy adults completed a double-blind, placebo-controlled crossover study evaluating the effects of 7-9 days of metformin (final dose 2000 mg/d) on maximal aerobic capacity compared to placebo. Metformin significantly reduced VO2 peak (-2.7%), peak heart rate (-2.0%), peak ventilation (-6.2%), peak respiratory exchange ratio (-3.0%), and exercise duration (-4.1%) (all p<0.05). Metformin had no effect on rating of perceived exertion or ventilatory breakpoint, and correlations between the reduction in VO2 peak and other outcomes were weak and not significant.
- Study type
- Double-blind, placebo-controlled, crossover trial
- Who was studied
- 17 healthy, normal-weight men (n=11) and women (n=6)
- What was measured
- Peak aerobic capacity (VO2 peak, HR, VE, RER, RPE, exercise duration)
THE PAPER
Impact of metformin on peak aerobic capacity.
Braun B, Eze P, Stephens BR, Hagobian TA, Sharoff CG, Chipkin SR, Goldstein B. Appl Physiol Nutr Metab, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.